KRAS and neoplasm: It has been shown previously that in situ KPC PDAC tumours are less sensitive to GEM than KPC allografts despite their identical Kras and p53 genotypes, and this difference in sensitivity was attributed to limited drug delivery to the KPC tumours [18].